A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Trial end date:
2020-03-04
Target enrollment:
Participant gender:
Summary
The study objectives are to assess the potential for PLX3397 to improve the efficacy of
standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed
glioblastoma (GBM).